VeriChip to launch DTC campaign

Share this article:
VeriChip to launch DTC campaign
VeriChip to launch DTC campaign

The VeriChip Corporation, manufacturers of radio-frequency identification devices (RFID) for patients, launched its first DTC campaign in South Florida.

In conjunction with the campaign, which features print and TV ads, VeriChip renamed its patient identification system Health Link, and launched a new website. Health Link was designed to provide vital medical and emergency contact information to doctors and nurses. 

“Given our successful infrastructure build-out in South Florida, we are now ready to escalate our marketing efforts to increase consumer awareness and adoption through the first DTC launch of our product,” said Scott Silverman, chairman and CEO, in a statement.

VeriChip hired Samuel Ambros to lead the marketing effort as vice president of business development. The company announced a partnership with HearUSA and its HEARx centers to provide customers with easy access to the Health Link system. HEARx has eight locations throughout the Palm Beach market.

The Health Link RFID microchip is injected subcutaneously in the rear upper portion of the right arm. The microchip stores a 16-digit personal identification number. Emergency medical personnel can use the Health Link scanner to retrieve the number, and access to the patient's personal health record.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union